BRCA1-hapoinsufficiency: Unraveling the molecular and cellular basis for tissue-specific cancer
- 3 March 2016
- journal article
- review article
- Published by Taylor & Francis in Cell Cycle
- Vol. 15 (5) , 621-627
Abstract
Over the past 20 years tremendous progress has been made in understanding the function of BRCA1 gene products. Yet one question still remains: why is mutation of BRCA1 typically associated with preferential development of breast and ovarian cancers and not tumors in other tissues? Here we discuss recent evidence documenting the effect of BRCA1-haploinsufficiency in different cells and tissues and synthesize a model for how mutations in a single BRCA1 allele in human cells might preferentially confer increased cancer risk in breast epithelial cells.Keywords
This publication has 73 references indexed in Scilit:
- The role of BRCA1 in homologous recombination repair in response to replication stress: significance in tumorigenesis and cancer therapyCell & Bioscience, 2013
- Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cellsProceedings of the National Academy of Sciences, 2011
- Defining the cellular precursors to human breast cancerProceedings of the National Academy of Sciences, 2011
- Genetic Predisposition Directs Breast Cancer Phenotype by Dictating Progenitor Cell FateCell Stem Cell, 2011
- Expression and Function of a Large Non‐coding RNA Gene XIST in Human CancerWorld Journal of Surgery, 2011
- Preclinical mouse models for BRCA1-associated breast cancerBritish Journal of Cancer, 2009
- BRCA1 regulates human mammary stem/progenitor cell fateProceedings of the National Academy of Sciences, 2008
- X Inactive–Specific Transcript RNA Coating and Genetic Instability of the X Chromosome in BRCA1 Breast TumorsCancer Research, 2007
- Estrogen receptor α is a putative substrate for the BRCA1 ubiquitin ligaseProceedings of the National Academy of Sciences, 2007
- Mapping loss of heterozygosity in normal human breast cells from BRCA1/2 carriersBritish Journal of Cancer, 2006